Comparison of Intravitreal Bevacizumab and Triamcinolone With Placebo
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01330524 |
Recruitment Status : Unknown
Verified November 2009 by Shahid Beheshti University of Medical Sciences.
Recruitment status was: Recruiting
First Posted : April 7, 2011
Last Update Posted : April 7, 2011
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Acute Nonarteritic Anterior Ischemic Optic Neuropathy | Drug: Avastin and Triamcinolone Other: placebo | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 16 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Comparison of Intravitreal Bevacizumab and Triamcinolone With Placebo in Acute Nonarteritic Anterior Ischemic Optic Neuropathy |
Study Start Date : | January 2010 |
Estimated Primary Completion Date : | November 2010 |
Estimated Study Completion Date : | November 2011 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Avastin and Triamcinolone |
Drug: Avastin and Triamcinolone
1.25 mg Avastin and 2mg Triamcinolone will be injected trough vitreal |
Placebo Comparator: Placebo |
Other: placebo
2mg placebo |
- Changes of Best corrected visual acuity(BCVA) [ Time Frame: 6 month ]outcome method of measurement: Snellen chart
- Changes of Visual Field [ Time Frame: 6 month ]Automated perimeter

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion criteria:
- Sudden mono ocular vision loss associated with optic disc edema and positive Marcus Gunn (<30 days)
Exclusion criteria:
- Any eye disease except NAION(Nonarteritic Anterior Ischemic Optic Neuropathy)
- Neurologic defect
- Abnormal ESR, CRP, any history of retina or vitreal surgery
- Severe corneal opacity which makes retina examination impossible

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01330524
Iran, Islamic Republic of | |
Labbafinejad medical center | Recruiting |
Tehran, Iran, Islamic Republic of | |
Contact: morteza entezari, Associate Professor 00982122585952 entmort@hotmail.com | |
Principal Investigator: morteza entezari, associat of profesor |
Responsible Party: | morteza entezari, Ophthalmic Research center |
ClinicalTrials.gov Identifier: | NCT01330524 |
Other Study ID Numbers: |
8749 |
First Posted: | April 7, 2011 Key Record Dates |
Last Update Posted: | April 7, 2011 |
Last Verified: | November 2009 |
Optic Nerve Diseases Optic Neuropathy, Ischemic Cranial Nerve Diseases Nervous System Diseases Eye Diseases Vascular Diseases Cardiovascular Diseases Triamcinolone Bevacizumab Antineoplastic Agents, Immunological |
Antineoplastic Agents Angiogenesis Inhibitors Angiogenesis Modulating Agents Growth Substances Physiological Effects of Drugs Growth Inhibitors Anti-Inflammatory Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists |